The Role of Testin in Human Cancers.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 29 11 2017
accepted: 10 10 2018
pubmed: 26 10 2018
medline: 31 3 2020
entrez: 26 10 2018
Statut: ppublish

Résumé

Testin is a protein expressed in almost all normal human tissues. It locates in the cytoplasm along stress fibers being recruited to focal adhesions. Together with zyxin and vasodilator stimulated protein it forms complexes with various cytoskeleton proteins such as actin, talin and paxilin. They jointly play significant role in cell motility and adhesion. In addition, their involvement in the cell cycle has been demonstrated. Expression of testin protein level correlates positively with percentage of cells in G1 phase, while overexpression can induce apoptosis and decreased colony forming ability. Decreased testin expression associate with loss by cells epithelial morphology and gain migratory and invasive properties of mesenchymal cells. Latest reports indicate that TES is a tumor suppressor gene which can contribute to cancerogenesis but the mechanism of loss TES gene expression is still unknown. Some authors point out hypermethylation of the CpG island as a main factor, however loss of heterozygosity may also play an important role [4, 5]. The altered expression of testin was found in malignant neoplasm, i.a. ovarian, lung, head and neck squamous cell cancer, breast, endometrial, colorectal, prostate and gastric cancers [1-9]. Testin participate in the processes of tumor growth, angiogenesis, and metastasis [10]. Many researchers stated involvement of testin in tumor progression, what suggest its potential usage in immunotherapy [7, 11]. Understanding the molecular functions of testin may be crucial in development personalized treatment. In the present manuscript up-to-date review of literature can be found.

Identifiants

pubmed: 30357755
doi: 10.1007/s12253-018-0488-3
pii: 10.1007/s12253-018-0488-3
pmc: PMC6815323
doi:

Substances chimiques

Cytoskeletal Proteins 0
RNA-Binding Proteins 0
TES protein, human 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1279-1284

Références

Cell Motil Cytoskeleton. 2004 Mar;57(3):133-42
pubmed: 14743347
Oncogene. 2007 Jan 25;26(4):583-93
pubmed: 16909125
Hepatology. 2011 Nov;54(5):1729-40
pubmed: 21793034
Leuk Res. 1999 Mar;23(3):307-10
pubmed: 10071086
Prostate. 2013 Jun;73(8):835-41
pubmed: 23255296
Sci Rep. 2015 Nov 27;5:17225
pubmed: 26611125
J Proteome Res. 2017 May 5;16(5):2054-2071
pubmed: 28378594
Mol Cell Biochem. 2009 Jan;320(1-2):85-92
pubmed: 18696217
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cancer Sci. 2017 Jan;108(1):5-11
pubmed: 27862655
Int J Cancer. 2004 Sep 20;111(5):798-804
pubmed: 15252854
World J Gastroenterol. 2014 Aug 7;20(29):9744-58
pubmed: 25110412
Genomics. 2000 Aug 15;68(1):1-12
pubmed: 10950921
Breast Cancer Res. 2010;12(3):R36
pubmed: 20565864
Oncol Rep. 2013 Aug;30(2):824-32
pubmed: 23715752
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10947-51
pubmed: 16033868
Protoplasma. 2002 Feb;219(1-2):1-12
pubmed: 11926060
Cancer Res. 1996 Aug 15;56(16):3808-13
pubmed: 8706028
Oncotarget. 2017 Mar 21;8(12):20198-20212
pubmed: 28423626
Cancer Sci. 2010 May;101(5):1255-60
pubmed: 20180808
J Cell Sci. 2003 Mar 1;116(Pt 5):897-906
pubmed: 12571287
Mol Cancer. 2010 Jul 13;9:190
pubmed: 20626849
Cancer Res. 1995 Mar 15;55(6):1347-50
pubmed: 7882334
PLoS One. 2017 May 18;12(5):e0177879
pubmed: 28542564
PLoS One. 2016 Mar 17;11(3):e0151341
pubmed: 26985820
Oncol Lett. 2016 Nov;12(5):3305-3311
pubmed: 27899997
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):806-13
pubmed: 15701871
Mol Cell. 2007 Dec 28;28(6):1071-82
pubmed: 18158903
APMIS. 2015 May;123(5):394-400
pubmed: 25720371
Oncotarget. 2016 Jul 19;7(29):45819-45836
pubmed: 27323777
Anticancer Res. 1998 Jan-Feb;18(1A):453-8
pubmed: 9568119
Arch Otolaryngol Head Neck Surg. 2009 Mar;135(3):254-60
pubmed: 19289703
Cell Cycle. 2007 Oct 15;6(20):2429-33
pubmed: 17957136
Genomics. 2003 Feb;81(2):105-7
pubmed: 12620387
Mol Cancer. 2010 Jun 24;9:163
pubmed: 20573277
Clin Cancer Res. 1997 Jun;3(6):1009-16
pubmed: 9815778
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Feb;30(4):310-3
pubmed: 27373040
Med Sci Monit. 2014 Jun 14;20:980-7
pubmed: 24929083
Oncol Rep. 2017 Feb;37(2):1027-1035
pubmed: 28000866
Cancer Sci. 2012 Dec;103(12):2092-101
pubmed: 22957844
Gynecol Oncol Res Pract. 2017 Feb 22;4:4
pubmed: 28250960
Cancer Cell Int. 2017 May 19;17:56
pubmed: 28533703
Med Oncol. 2017 Jul;34(7):122
pubmed: 28560682
Ai Zheng. 2008 Sep;27(9):984-8
pubmed: 18799041
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H919-30
pubmed: 22904159
Oncogene. 1997 Nov 27;15(22):2727-33
pubmed: 9400999
Oncogene. 2001 May 17;20(22):2844-53
pubmed: 11420696

Auteurs

Aneta Popiel (A)

Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland. aneta.popiel@live.com.
Wroclaw Medical University, Wroclaw, Poland. aneta.popiel@live.com.

Christopher Kobierzycki (C)

Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland.

Piotr Dzięgiel (P)

Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH